Article
Cell signaling pathways as molecular targets to eliminate AML stem cells
Registro en:
RODRIGUES, Ana Carolina Borges da Cruz et al. Cell signaling pathways as molecular targets to eliminate AML stem cells. Critical Reviews in Oncology/Hematology, v. 160, p. 1-22, Apr. 2021.
1040-8428
10.1016/j.critrevonc.2021.103277
Autor
Rodrigues, Ana Carolina Borges da Cruz
Costa, Rafaela G. A.
Silva, Suellen L. R.
Dias, Ingrid R. S. B.
Dias, Rosane Borges
Bezerra, Daniel Pereira
Resumen
Fundação de Amparo à Pesquisa da Bahia (FAPESB, Brazil) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES, Brazil) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil) Acute myeloid leukemia (AML) remains the most lethal of leukemias and a small population of cells called leukemic stem cells (LSCs) has been associated with disease relapses. Some cell signaling pathways play an important role in AML survival, proliferation and self-renewal properties and are abnormally activated or suppressed in LSCs. This includes the NF-κB, Wnt/β-catenin, Hedgehog, Notch, EGFR, JAK/STAT, PI3K/AKT/mTOR, TGF/SMAD and PPAR pathways. This review aimed to discuss these pathways as molecular targets for eliminating AML LSCs. Herein, inhibitors/activators of these pathways were summarized as a potential new anti-AML therapy capable of eliminating LSCs to guide future researches. The clinical use of cell signaling pathways data can be useful to enhance the anti-AML therapy.